IFM | New Oral Medication to Prevent COVID-19 After Exposure

In this special sponsored episode of the Inside Family Medicine podcast, brought to you by Shionogi, host Darren Sextro talks with family physician Ben Silverberg, MD, about ensitrelvir, a newly approved oral medication for COVID-19 post-exposure prophylaxis (PEP).

Dr. Silverberg explains how the medication works to inhibit viral replication and discusses findings from the Phase III SCORPIO-PEP trial, which evaluated ensitrelvir among household contacts of people with confirmed COVID-19. The conversation highlights the importance of starting post-exposure prophylaxis quickly, along with safety considerations, potential drug interactions and factors family physicians may evaluate when determining whether a patient may be eligible.

The discussion also explores how this new option may fit alongside vaccination and other COVID-19 prevention strategies, particularly during respiratory illness season. Dr. Silverberg discusses patients who may benefit from a conversation about PEP after a known exposure, including older adults, people with chronic conditions, individuals who are not up to date on vaccination and those who may face significant challenges if they become ill. Throughout the episode, he emphasizes the role family physicians can play in helping patients understand their options and navigate COVID-19 prevention as the virus continues to evolve.

References and resources

• Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts — New England Journal of Medicine

• Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure

AAFP resources related to COVID-19 prevention

• Immunizations And Vaccines For Family Physicians | AAFP

• COVID-19 antiviral treatment | Family Doctor

Topics by timestamp

00:00 Introduction
01:27 A new option for COVID-19 post-exposure prevention
01:58 What is ensitrelvir and how does it work?
03:21 Preventing COVID-19 spread within households
03:46 Clinical considerations for family physicians
04:03 Inside the SCORPIO-PEP trial
05:00 Effectiveness and importance of early treatment
05:29 Safety profile and adverse events
06:12 Which patients may be appropriate candidates?
07:00 Patients who may benefit during respiratory season
07:23 Key takeaways for talking with patients
07:43 Vaccination and post-exposure prophylaxis
08:18 Closing thoughts and COVID-19 resources

This episode is brought to you by Shionogi.

Disclaimer: Copyright 2026. AAFP. The views presented in this broadcast are the speaker's own and do not represent those of AAFP. The information presented is for general, educational, or entertainment purposes and should not be considered legal, health, financial, or other advice.  AAFP makes no representation as to the accuracy or completeness of the information and is not responsible for results that may arise from its use.  Consult an appropriate professional concerning your specific situation and respective governing bodies for applicable laws. Reference to any specific product or entity does not constitute an endorsement or recommendation by AAFP unless specifically stated otherwise.  AAFP and the AAFP logo are registered trademarks of American Academy of Family Physicians.